-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Nypga0c0SveOsREH5eRFZXR3RBhW9tFdynabJL0FJrLXWjZXN2DWBvt7nUwMIwZl
 aA/97TJfOfy4QeSRIdQU4A==

<SEC-DOCUMENT>0001102624-04-000061.txt : 20040420
<SEC-HEADER>0001102624-04-000061.hdr.sgml : 20040420
<ACCEPTANCE-DATETIME>20040420141750
ACCESSION NUMBER:		0001102624-04-000061
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20040420
ITEM INFORMATION:		
ITEM INFORMATION:		Financial statements and exhibits
FILED AS OF DATE:		20040420

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUCELL CORP /DE/
		CENTRAL INDEX KEY:			0000811641
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				010382980
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12934
		FILM NUMBER:		04742519

	BUSINESS ADDRESS:	
		STREET 1:		56 EVERGREEN DR
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
		BUSINESS PHONE:		2078782770

	MAIL ADDRESS:	
		STREET 1:		56 EVERGREEN DRIVE
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>immucellcorp8k.htm
<DESCRIPTION>IMMUCELL CORP 8-K
<TEXT>
<table cellpadding="3" border="0" cellspacing="0" width="100%">
<tr><td>
</td></tr>
</table>
<center>
<table border=0 cellpadding=3 cellspacing=0>
<tr><td align="center"><br><br>
<B>UNITED STATES</B><br>
<B>SECURITIES AND EXCHANGE COMMISSION</B><br>
Washington, D.C. 20549<p>
<hr size=1>
<p><b>FORM 8-K<p>
CURRENT REPORT
<p>
Pursuant to Section 13 or 15(d) of the<br>Securities Exchange Act of 1934.
</td>
</tr>
</table>
<p>
<b>
<table border=0 cellpadding=0 cellspacing=0>
<tr><td colspan=5 align=center>
<b>Date of Report: April     20, 2004</b><br>
(Date of earliest event reported)<br><br>
</td></tr>
<tr><td colspan=5 align=center>
<b>ImmuCell Corporation</b><br>
(Exact name of registrant as specified in its charter)
</td></tr>
<tr>
<td align=center width="20%">
<b>DE</b><br>
(State or other jurisdiction of incorporation)
</td>
<td width="20%">
&nbsp;
</td>
<td align=center width="20%">
<b>0-15507</b><br>
(Commission File Number)
</td>
<td width="20%">
&nbsp;
</td>
<td align=center width="20%">
<b>01-0382980</b><br>
(IRS Employer Indentification Number)
</td>
</tr>
<tr>
<td width="20%">
&nbsp;
</td>
<td align=center width="20%" colspan=2>
<b>56 Evergreen Drive, Portland, ME</b><br>
(Address of principal executive offices)
</td>
<td align=center width="20%" colspan=2>
<b>04103</b><br>
(Zip Code)
</td>
<td width="20%">
&nbsp;
</td>
</tr>
<tr><td colspan=5 align=center>
<br>Registrant's telephone number, including area code: <b>(207) 878-2770</b>
</td></tr>
</table>
</center>
<hr size=1>
<table width=100%>
<tr><td width="100%">
<b>Item 7. Financial Statements and Exhibits</b></b><br>
(a) Not Applicable
<br>(b) Not Applicable
<br>(c) Exhibits
<p>
99.1 &nbsp; &nbsp; &nbsp; <a href="immucellcorporation.htm">Press Release of ImmuCell Corporation dated April     20, 2004</a></b>
<p>
<b>Item 12. Results of Operations and Financial Condition</b></b><br>
<br>
On April 20, 2004, ImmuCell Corporation(the "Company") issued a press release announcing earnings results for the three month period ended March 31, 2004. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.
<br>
<br>The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exhange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 of the Exchange Act, except as expressly set forth by specific reference in such filing.
<p>
<p>
<hr size=1>
<b><center>SIGNATURE</center></b>
<p>
&nbsp; &nbsp; &nbsp; Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
              signed on its behalf by the undersigned hereunto duly authorized.<p>
</td></tr>
</table>
<table>
<tr>
<td width="50%" valign=top>
Dated: April     20, 2004<br>
</td>
<td>
<b>IMMUCELL CORPORATION</b>
<p>
By: <u>&nbsp;/s/ Michael F. Brigham &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; </u> <br>
&nbsp; &nbsp; &nbsp;Michael F. Brigham<br>
&nbsp; &nbsp; &nbsp;<i>President/CEO</i><br>
</td></tr>
</table>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1 CHARTER
<SEQUENCE>3
<FILENAME>immucellcorporation.htm
<DESCRIPTION>IMMUCELL CORP PRESS RELEASE
<TEXT>

<p></p>
<b>ImmuCell Announces 20% Sales Growth and Other Financial Results for First Quarter of 2004</b>
<p>PORTLAND, ME -- 04/20/2004 --  ImmuCell Corporation (NASDAQ: ICCC) today
announced the results of its operations for the three months ended March
31, 2004.
</p>
<p>
During the three months ended March 31, 2004, product sales increased by
20%, or $202,000, to $1,218,000, as compared to the same period in 2003.
During the three months ended March 31, 2004, total revenue increased by
10%, or $114,000, to $1,242,000, as compared to the same period in 2003.
No grant income was recognized in the 2004 period, as compared to $81,000
in the 2003 period.
</p>
<p>
"Our product sales have benefited from the higher milk prices that are
being realized currently by dairy producers, during the peak season for
First Defense&#174; sales," commented Michael F. Brigham, president and CEO.
"We move forward focused on maintaining and growing sales, while investing
aggressively in the development of Mast Out&#174; during the balance of the
year."
</p>
<p>
During the three months ended March 31, 2004, research and development
expenses decreased by 30%, or $94,000, to $222,000, comprising 18% of total
revenues in 2004.  The primary focus of the Company's research and
development efforts continues to be Mast Out, its Nisin-based mastitis
treatment product.
</p>
<p>
Income before income taxes decreased by 75%, or $889,000, to $290,000
during the three months ended March 31, 2004, as compared to $1,179,000
during the same period in 2003. In the first quarter of 2003, the Company
recognized $1,100,000 in other income from the sale of its interest in a
non-core joint venture.  Net income of $172,000, or $0.06 per share, during
the three months ended March 31, 2004, decreased by 75%, or $529,000, from
$701,000, or $0.25 per diluted share, during the same period in 2003.
</p>
<p>
The Company's cash and short-term investments increased by $15,000 to
$4,261,000 at March 31, 2004, as compared to $4,245,000 at December 31,
2003.  Stockholders' equity increased by 3%, or $208,000, to $7,579,000 at
March 31, 2004, as compared to $7,370,000 at December 31, 2003.   As of
March 31, 2004, the Company had 2,757,817 shares of common stock
outstanding, and 551,639 shares were reserved for outstanding stock
options.
<pre>
                                                     (Unaudited)
                                             Three Months Ended March 31,
                                             ----------------------------
(In thousands, except per share amounts)        2004              2003
                                                ----              ----
Revenues:
Product sales                                 $1,218            $1,016
Other revenues                                    24               111
                                              ------            ------
Total revenues                                 1,242             1,127

Cost and expenses:
Product costs                                    459               424
Research and development expenses                222               316
Selling, general and administrative expenses     281               317
                                              ------            ------
Total costs and expenses                         962             1,057
                                              ------            ------
Net operating income                             279                70

Interest and other income, net  (1)               11             1,109
                                              ------            ------
Income before income taxes                       290             1,179
Income tax expense                               118               478
                                              ------            ------
Net income                                    $  172            $  701
                                              ======            ======
Net income per common share:
Basic                                         $ 0.06            $ 0.26
Diluted                                       $ 0.06            $ 0.25

Weighted average common shares outstanding:
Basic                                          2,743             2,736
Diluted                                        2,933             2,779
</pre>
(1) Includes $1,100,000 in other income from the sale of a non-core joint
venture in the 2003 period.
<pre>
                                   (Unaudited)
                                At March 31, 2004    At December 31, 2003
                                -----------------    --------------------
(In thousands, except
 per share amounts)
Cash and short-term investments       $4,261               $4,245
Total assets                           8,243                8,187
Net working capital                    5,189                4,965
Stockholders' equity                  $7,579               $7,370
</pre>
ImmuCell Corporation is a biotechnology company that is developing products
intended to help reduce the overuse of antibiotics in animal and human
healthcare and is manufacturing and selling other products that improve
animal health and productivity in the dairy and beef industry.  ImmuCell
Corporation press releases and other information about the Company are
available at its corporate web site at http://www.immucell.com.

</p>
<pre>
Contact:

Michael F. Brigham
President and Chief Executive Officer
(207) 878-2770 Ext. 3106


</pre>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
